Last reviewed · How we verify

Buprenorphine transdermal patches

Mundipharma (China) Pharmaceutical Co. Ltd · Phase 3 active Small molecule

Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to provide analgesia and reduce opioid cravings.

Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to provide analgesia and reduce opioid cravings. Used for Chronic moderate to severe pain, Opioid use disorder (maintenance treatment).

At a glance

Generic nameBuprenorphine transdermal patches
SponsorMundipharma (China) Pharmaceutical Co. Ltd
Drug classPartial mu-opioid receptor agonist
TargetMu-opioid receptor (μ-OR)
ModalitySmall molecule
Therapeutic areaPain Management / Addiction Medicine
PhasePhase 3

Mechanism of action

Buprenorphine's partial agonist activity at the mu-opioid receptor produces a ceiling effect on respiratory depression, making it safer than full opioid agonists. The transdermal patch formulation provides sustained drug delivery over several days, improving compliance and reducing fluctuations in plasma levels. This mechanism makes it suitable for both chronic pain management and opioid use disorder treatment.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: